Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Heron Therapeutics, Inc. (HRTX : NSDQ)

• Company Description    Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. Number of Employees: 128

• Price / Volume Information    Yesterday's Closing Price: $0.46 Daily Weekly Monthly 20 Day Moving Average: 2,841,581 shares Shares Outstanding: 189.28 (millions) Market Capitalization: $86.27 (millions) Beta: 1.65 52 Week High: $1.93 52 Week Low: $0.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.17% 10.35% 12 Week -62.02% -63.06% Year To Date -64.94% -67.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 25 FENTON MAIN STREET SUITE 300 - CARY,NC 27511 USA ph: 858-251-4400 fax: 650-365-6490 info@herontx.com http://www.herontx.com

• General Corporate Information    Officers Craig Collard - Chief Executive Officer and Director Adam Morgan - Chairman Ira Duarte - Executive Vice President; Chief Financial Officer Tom Cusack - Director Sharmila Dissanaike - Director Peer Information Heron Therapeutics, Inc. (GSAC) Heron Therapeutics, Inc. (CASIF) Heron Therapeutics, Inc. (ALCD.) Heron Therapeutics, Inc. (OMNN) Heron Therapeutics, Inc. (CGPI.) Heron Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 427746102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 189.28 Most Recent Split Date: 1.00 (0.05:1) Beta: 1.65 Market Capitalization: $86.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.09 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.63 Price/Cash Flow: - Price / Sales: 0.57 EPS Growth vs. Year Ago Period: -500.00% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: -10.78% vs. Previous Quarter: -14.48% ROE 06/30/26 - - 03/31/26 - -7,747.30 12/31/25 - - ROA 06/30/26 - - 03/31/26 - -8.94 12/31/25 - -4.62 Current Ratio 06/30/26 - - 03/31/26 - 2.53 12/31/25 - 2.48 Quick Ratio 06/30/26 - - 03/31/26 - 1.51 12/31/25 - 1.51 Operating Margin 06/30/26 - - 03/31/26 - -14.59 12/31/25 - -7.25 Net Margin 06/30/26 - - 03/31/26 - -20.53 12/31/25 - -13.04 Pre-Tax Margin 06/30/26 - - 03/31/26 - -20.53 12/31/25 - -13.04 Book Value 06/30/26 - - 03/31/26 - 0.04 12/31/25 - 0.07 Inventory Turnover 06/30/26 - - 03/31/26 - 0.53 12/31/25 - 0.57 Debt-to-Equity 06/30/26 - - 03/31/26 - 17.51 12/31/25 - 10.59 Debt-to-Capital 06/30/26 - - 03/31/26 - 93.94 12/31/25 - 90.75

Powered by Zacks Investment Research ©